Metformin Use and Development of Esophageal Squamous Cell Carcinoma

Dose use of metformin reduce the risk of developing esophageal squamous cell carcinoma (ESCC)?In this case-control study with 13 050 patients with ESCC and 130 500 control participants, metformin use was associated with 36% lower odds of ESCC. This was more profound among high-dosage users.These findings suggest metformin use may have preventive potential against ESCC, which warrants further evaluation.

Corresponding Author: Shao-Hua Xie, MD, PhD, Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Blombäcks väg 23, 4th Floor, 17177 Stockholm, Sweden (shaohua.xie@ki.se).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.